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Transcriptomic profiling reveals disease-
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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is an incurable disease characterized by progressive lung fibrosis
ultimately resulting in respiratory failure and death. Recurrent micro-injuries to the alveolar epithelium and aberrant
alveolar wound healing with impaired re-epithelialization define the initial steps of the pathogenic trajectory. Failure
of timely alveolar epithelial repair triggers hyper-proliferation of mesenchymal cells accompanied by increased
deposition of extracellular matrix into the lung interstitium.
Methods: We previously isolated fibrosis-specific mesenchymal stem cell (MSC)-like cells from lung tissue of
patients with interstitial lung diseases. These cells produced factors bearing anti-fibrotic potential and changed their
morphology from mesenchymal to epithelial upon culture in an epithelial cell (EC)-specific growth medium. Here,
we set out to molecularly characterize these MSC-like cell-derived ECs using global gene expression profiling by
RNA-sequencing. Moreover, we aimed at characterizing disease-specific differences by comparing the
transcriptomes of ECs from IPF and non-IPF sources.
Results: Our results suggest that differentially expressed genes are enriched for factors related to fibrosis, hypoxia,
bacterial colonization and metabolism, thus reflecting many of the hallmark characteristics of pulmonary fibrosis.
IPF-ECs showed enrichment of both pro- and anti-fibrotic genes, consistent with the notion of adaptive,
compensatory regulation.
Conclusions: Our findings support the hypothesis of a functional impairment of IPF-ECs, which could possibly
explain the poor clinical outcome of IPF that roughly compares to those of advanced-stage cancers. Our study
provides a valuable resource for downstream mechanistic investigation and the quest for novel therapeutic IPF
targets.
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Background
Idiopathic pulmonary fibrosis (IPF) is an incurable inter-
stitial lung disease (ILD) characterized by progressive fi-
brosis and worsening dyspnea, ultimately leading to
respiratory failure and death [1, 2]. The prognosis of IPF
is markedly poor, with survival rates comparing to those
of advanced-stage cancers [2, 3]. Although the under-
lying pathomechanisms are incompletely understood, it
is generally believed that ongoing damage to the alveolar
epithelium triggers a secondary fibrotic response in
lung-resident fibroblasts that further impinges on lung
function [4, 5]; formal support for this concept for IPF
pathogenesis came from mechanistic studies in mice [6,
7]. The appreciation of IPF as a predominantly fibrotic,
rather than inflammatory, condition [2, 8] has paved the
way for new anti-fibrotic medicines including nintedanib
[9] and pirfenidone [10].
Recently, we succeeded in isolating MSC-like cells
from peripheral human fibrotic lung tissue. The MSC-
like cells met the defining criteria of mesenchymal stem
cells (MSCs) [11]. Specifically, the cells stained positive
for the surface markers CD44, CD90 and CD105, and
were able to differentiate into various cell types of the
mesenchymal lineage, including adipocytes, osteocytes
and chondrocytes. Furthermore, the cells expressed the
pluripotency-associated markers Oct-3/4 and Nanog,
thus indicating their potential stemness. Of note, MSC-
like cells changed their mesenchymal look to a bona fide
(cobblestone-like) epithelial morphology when cultured
in epithelial cell (EC)-specific growth medium. This dis-
tinct change in morphology was paralleled by induction
of E-cadherin (CD324) expression, a canonical marker of
ECs [5].
Here, we sought to determine the transcriptomic dif-
ferences between these MSC-like cell-derived ECs from
IPF and non-IPF sources. We further aimed at delineat-
ing the phenotypic properties of these ECs, following the
goal to elucidate a possible functional involvement of
these cells in IPF, which may help to explain the poor
clinical outcome of IPF as compared to other types of
ILDs.
Methods
Isolation of primary lung-resident MSC-like cells
Characteristics of the study population are specified in
Table 1. MSC-like cells were isolated from lung bron-
choscopic or surgical biopsies of IPF (n = 5) and non-
IPF ‘control’ patients (n = 5) between November 2015
and November 2016 as previously described [5]. Briefly,
the harvested lung tissue was chopped into pieces (~ 1
mm3) which were then cultured in tissue flasks under
standard conditions (37 °C, 21% O2, 5% CO2) in DMEM
supplemented with fetal bovine serum (10%), penicillin
(20 U/l), streptomycin (20 μg/ml), and amphotericin B
(2.5 μg/ml). MSC-like cells showed sprouting-like
growth emanating from the tissue samples and finally
formed a confluent cell monolayer around the tissue
piece. The non-adherent cell fraction was washed away
over the course of the culture through repeated ex-
change of medium. After 5 days, the tissue pieces were
removed and the medium was exchanged for the EC-
specific growth medium Cnt-17 (CELLnTEC Advanced
Cell Systems AG, Bern, Switzerland). Total RNA was ex-
tracted after 7 days of culture in Cnt-17.
RNA extraction
Total RNA was extracted from ECs (bulk populations)
using the MicroElute Total RNA Kit (Omega Bio-Tek,
Norcross, GA). RNA was quantified using the Quanti-
Fluor RNA System (Promega, Madison, WI) and quality-
controlled on the Bioanalyzer instrument using the RNA
6000 Pico Kit (both from Agilent, Santa Clara, CA).
RNA-sequencing
Fifty ng total RNA were used for library generation using
the TruSeq Stranded mRNA Library Prep Kit High
Throughput (Illumina, San Diego, CA), and 15 PCR cy-
cles were performed. The Standard Sensitivity NGS
Fragment Analysis Kit (Advanced Analytical, Ames, IA)
was used to assess the quality of the libraries (123 ± 30
nmol/L average concentration and 321 ± 8 bp average li-
brary size). 1.8 pM of pooled sample was used for cluster
generation on the NextSeq 500 instrument (Illumina).
Single-read 76 bases (plus 8 + 8 bases for indexing) were
sequenced using the NextSeq 500 High Output Kit 75-
cycles (Illumina). Primary analysis of sequencing data
was conducted using RTA version 2.4.11 and bcl2fastq
v2.20.0.422 (both from Illumina).
Table 1 Patient Characteristics (n = 10)
Patient ID Sex Age (years) Clinical Diagnosis
IPF (n = 5)
001 Male 65 IPF
002 Male 63 IPF
003 Female 49 IPF
004 Male 77 IPF
005 Male 60 IPF
Non-IPF (n = 5)
006 Male 37 Non-classifiable ILD
007 Male 67 Vasculitis-associated ILD
008 Male 71 Non-classifiable ILD
009 Female 75 Carcinoma
010 Male 72 Chronic eosinophilic pneumonia
Abbreviations used: IPF Idiopathic pulmonary fibrosis; ILD Interstitial
lung disease
Boesch et al. Respiratory Research          (2020) 21:165 Page 2 of 9
qPCR validation
Total RNA was isolated from additional samples of an
independent cohort and gene expression levels were de-
termined using TaqMan® Gene Expression Assays
(Thermo Fisher Scientific, Waltham, MA). The following
target genes were analyzed: CXCL8 (Hs00174103 m1),
ICAM1 (Hs00164932 m1), PTGS2 (Hs00153133 m1),
LIF (Hs01055668 m1), IL7R (Hs00902334 m1), and
GAPDH/housekeeper (Hs03929097_g1). Reactions were
performed at 50 °C for 2 min (1 cycle), 95 °C for 10 min
(1 cycle), and 95 °C for 15 s followed by 60 °C for 1 min
(40 cycles). Relative expression data are shown as -ΔCt
of target gene-GAPDH.
Statistical and bioinformatic considerations
All analyses were done using the R statistical software (R
Core Team 2018, www.R-project.org). The Bioconductor
package ‘edgeR’ (version 3.24.3) was used for the identi-
fication of differentially expressed genes. Exploratory
analyses including Principal Component Analysis (PCA)
were performed using the package ‘ade4’. Pathway en-
richment analyses and visualization were done using the
package ‘clusterProfiler’ (version 3.10.1) [12]. Differen-
tially expressed gene overrepresentation in various func-
tional annotation databases including Gene Ontology
(GO, http://geneontology.org), Kyoto Encyclopedia of
Genes and Genomes (KEGG, www.genome.jp/kegg/
pathway.html) and DisGeNET (www.disgenet.org/rdf)
was investigated using hypergeometric tests as imple-
mented in clusterProfiler.
Results
Transcriptomic profiling of ECs
We isolated primary MSC-like cells from bronchoscopic
or surgical biopsies of patients with IPF (n = 5) and non-
IPF lung disease (‘control’; n = 5) (Table 1). While we
previously showed that MSC-like cells exhibit EC
morphology when cultured in an EC-specific growth
Fig. 1 RNA-Sequencing of MSC-Like Cell-Derived ECs. a Conceptual and experimental design of the study. b PCA scores of ECs from IPF and non-
IPF sources. c Heatmap representation and hierarchical cluster analysis of global gene expression in IPF versus non-IPF samples. A total of 199
genes were differentially regulated in IPF versus non-IPF samples. d Expression of epithelial-related markers in ECs from IPF and non-IPF sources.
Abbreviations used: CPM, counts per million (reads mapped); EC, epithelial cell; IPF, idiopathic pulmonary fibrosis; MSC, mesenchymal stem cell;
PCA, Principal Component Analysis
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medium [5], we here set out to molecularly characterize
these ECs using global expression profiling by RNA-
sequencing (Fig. 1a). Despite quite some variation
between samples, PCA separated IPF from non-IPF sam-
ples on the two first principal components (Fig. 1b), in-
dicating disease-specific transcriptomic differences. A
differential expression analysis revealed the differential
expression of 199 genes between IPF and non-IPF (FDR-
adjusted p-values < 0.05) (Fig. 1c). Of note, epithelial
markers including EPCAM, CDH1 (encoding E-
cadherin/CD324) and keratins displayed only minor,
non-statistically significant differences between IPF and
non-IPF (FDR-adjusted p-values > 0.05) (Fig. 1d).
Principal signatures of ECs from an IPF source
We annotated the up- (n = 80) and downregulated genes
in IPF (n = 119) (Supplementary Table 1) using func-
tional enrichment analysis on the biological processes of
the GO database. We found that IPF-ECs were enriched
in various pathways potentially related to IPF pathogen-
esis including signatures specific for hypoxia, response
to microbes, and organ development (Fig. 2a). Con-
versely, pathways related to ion homeostasis/transport as
well as glycosylation were enriched for downregulated
genes (Fig. 2b). We specifically analyzed the differentially
expressed genes with respect to gene sets/pathways that
likely play a role in the development and/or progression
of IPF – ‘response to hypoxia’, ‘response to molecule of
bacterial origin’ and ‘lung morphogenesis’ (Fig. 2c). Be-
tween 4 and 9 differentially expressed genes could be al-
located to these pathways (of which some were
overlapping between the signatures) and included adhe-
sion molecules (ICAM1), chemokines (CXCL8), growth
factors (CSF2), growth factor receptors (TGFBR2),
matrix metalloproteinases (MMP10), and stem cell-
related factors (SOX11, SHH, LIF). Notably, some of the
genes were previously reported to be involved in pul-
monary fibrosis pathogenesis [13–15]. We next per-
formed functional enrichment analysis of the
differentially expressed genes using the KEGG pathway
database. Although inflammation is no longer consid-
ered the main driving force behind IPF development and
progression [2, 8], this analysis showed enrichment of
various immune-related pathways in IPF-ECs, including
the TNF, IL-17, and JAK-STAT signaling pathways (p <
0.05) (Fig. 3a+b). It should be noted, though, that these
signatures largely involved the same differentially
expressed genes as the enriched GO categories (Fig. 2).
Fig. 2 Functional Pathway Annotation Using GO Enrichment Analysis. Functional enrichment analysis of upregulated (a) and downregulated
pathways (b) in IPF-ECs using GO annotations. (c) In-depth analysis of three upregulated pathways that likely play a role in IPF pathogenesis.
Abbreviations used: CPM, counts per million (reads mapped); EC, epithelial cell; GO, Gene Ontology; IPF, idiopathic pulmonary fibrosis
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Moreover, quite some variation was observed within the
IPF and non-IPF groups (Fig. 3a), consistent with the
notion of significant interpatient variability. Using the
DisGeNET database to analyze the differentially
expressed genes with regards to IPF hallmark character-
istics, we found evidence that ECs from an IPF source
(‘IPF-ECs’) expressed fibrosis-associated genes, suggest-
ive of persistent ‘imprinting’ from the original IPF milieu
ex vivo (Fig. 4). We next set out to validate key genes
from the RNA-sequencing experiment using qPCR ana-
lysis of independent IPF and control patients (Supple-
mentary Table 2). As shown in Supplementary
Figure 1A, four out of five key genes (CXCL8, ICAM1,
LIF, PTGS2) could be validated as overexpressed in IPF,
with the remaining gene (IL7R) showing enrichment in
IPF samples as well without reaching statistical signifi-
cance. Moreover, comparing these key genes to the pub-
lically available GSE134692 dataset [16], we found that
three of the genes (CXCL8, LIF, PTGS2) showed the
same direction of regulation among IPF and non-IPF
samples, whereas ICAM1 and IL7R were differentially
regulated between the datasets (Supplementary Fig-
ure 1B). This suggested both similarities and character-
istic differences between the datasets, thus corroborating
our findings but also highlighting the distinct nature of
our ex vivo model in comparison to primary explanted
tissue. Moreover, the increasing appreciation of senes-
cence as a major contributor to IPF development [17]
prompted us to specifically investigate the KEGG path-
way ‘cellular senescence’. However, of the 160 genes al-
located to this pathway, only two (CXCL8 and TGFBR2)
were found to be overlapping with our dataset, suggest-
ing that this cellular process plays only a minor part in
IPF-ECs. Taken together, these data suggest that the
molecular signature of MSC-like cell-derived ECs may at
least partially reflect the biological situation in the IPF-
affected lung, including the hallmark characteristics (i)
compromised gas exchange, (ii) aberrant bacterial
colonization/dysbiosis, and (iii) developmental remodel-
ing/repair.
Functional pathway analysis reveals IPF-specific signaling
circuits
We moved on to interrogate the interconnection of the
differentially regulated pathways and biological processes
using the R package ‘clusterProfiler’. While pathways
enriched for downregulated genes in IPF-ECs did not
notably cluster (Fig. 5a), activated pathways showed
functional enrichment mostly within three clusters that
we termed ‘development’, ‘hypoxia and response to
Fig. 3 Functional Pathway Annotation Using KEGG Enrichment Analysis. a Heatmap analysis of functional pathway enrichment in IPF versus non-
IPF samples using KEGG annotations. b In-depth analysis of five immune-related pathways that demonstrate upregulation in ECs from an IPF
source. Abbreviations used: CPM, counts per million (reads mapped); EC, epithelial cell; IPF, idiopathic pulmonary fibrosis; KEGG, Kyoto
Encyclopedia of Genes and Genomes
Boesch et al. Respiratory Research          (2020) 21:165 Page 5 of 9
bacteria’, and ‘metabolism’ (Fig. 5b). Within the cluster
‘development’, several organ-specific developmental
pathways were identified, suggesting overlapping mecha-
nisms of tissue remodeling occurring in the IPF lung
and during embryonic development. In addition, enrich-
ment for development-related genes and pathways may
indicate stem cell potential of the ECs – in turn
necessary for epithelium-regenerating capacity. While
the cluster ‘metabolism’ may reflect the metabolic re-
quirements of a disease with a proliferative character,
the cluster ‘hypoxia and response to bacteria’ may be
more specific for IPF and reflect the typical conditions
in the IPF-affected lung, including low oxygen levels and
dysbiosis. Moreover, the pathway ‘collagen metabolic
Fig. 5 Analysis of Pathway Interrelation. Network analysis of functional pathways downregulated (a) and upregulated (b) in ECs from an IPF
source using the R package ‘clusterProfiler’. Significant clustering was manually delineated and the clusters were named based on their integrated
biological processes (B). Abbreviations used: EC, epithelial cell; IPF, idiopathic pulmonary fibrosis
Fig. 4 Expression Pattern of Fibrosis-Associated Genes in ECs. Comparative bar plot representation of the expression of 16 fibrosis-associated
genes in IPF versus non-IPF samples. The gene panel was retrieved from the DisGeNET database. Abbreviations used: CPM, counts per million
(reads mapped); EC, epithelial cell; IPF, idiopathic pulmonary fibrosis
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process’ within the same cluster may indicate the overt
fibrotic response in the diseased lung characterized at
least in part by massive collagen matrix deposition. Col-
lectively, comprehensive analysis of the interrelation of
pathways revealed distinct functional clusters that are
plausibly implicated in the pathogenesis of IPF.
Discussion
In this article, we provide a comprehensive description
of the transcriptomic landscape of MSC-like cell-derived
ECs from IPF versus non-IPF sources. Results from this
study suggest that IPF-ECs (i) remain imprinted from
the in vivo IPF milieu (hypoxia and dysbiosis), (ii) are
more fibrotic than ECs from non-IPF sources, (iii) are
enriched in various immune-related pathways, and (iv)
carry signatures associated with organ development and
cellular stemness. We therefore propose a distinct func-
tional failure of these cells in IPF, which may help to ex-
plain the poor clinical outcome of IPF patients.
It is important to note that ECs were experimentally
generated using a specific cell culture method and that
their in vivo relevance is yet to be determined. Overlap-
ping findings with the GSE134692 dataset based on pri-
mary tissue specimens from lung transplant recipients
and donors [16] suggest, however, that our model may
be able to capture the principal signatures of the IPF-
affected lung including upregulation of CXCL8, LIF, and
PTGS2. CXLC8 (encoding interleukin 8) is an inflamma-
tory mediator attracting neutrophils and contributing to
pathogen clearance, but may also confer secondary fi-
brotic tissue damage [18, 19]. In contrast, PTGS2 (en-
coding cyclooxygenase-2) [20, 21] and LIF [22] are
believed to counteract fibrosis through various mecha-
nisms including ferroptosis and immune modulation.
Their upregulation as seen here may therefore indicate
compensatory anti-fibrotic activity of the MSC-like cell-
derived ECs that warrants future investigation.
IPF is an age-related disease characterized by progres-
sive and irreversible scarring [23, 24]. The predominant
occurrence in the elderly population is in line with the
idea that cellular senescence drives, and is ultimately re-
sponsible for, pulmonary fibrosis [17]. While senescent fi-
broblasts have been shown to be fibrogenic and causally
involved in disease pathogenesis in the bleomycin-injury
IPF model [17], other studies have suggested a role for al-
veolar EC senescence in triggering lung remodeling and fi-
brosis [7, 25]. Mechanistically, adoption of a senescent
phenotypic state may result from mutations in the enzyme
telomerase reverse transcriptase, shortened telomeres, or
other telomere dysfunctions [7, 26]. The senescence of
functional (ECs) and/or structural (fibroblasts) lung cells
is thought to be ‘counteracted’ by increased proliferation
of non-senescent fibroblasts, with little success, finally
resulting in excessive matrix deposition and fibrosis/
scarring [27]. Indeed, we have looked at signatures of cel-
lular senescence without detecting relevant enrichment of
senescence-associated genes in IPF-ECs. We speculate
that this may be explainable by their derivation from lung-
resident stem-like cells rather than alveolar ECs or
fibroblasts.
Autophagy, i.e., the on-demand degradation and recyc-
ling of intracellular components and organelles, is yet
another fundamental cell process that is deregulated in
IPF. Diminished also during aging, the autophagy flux is
typically reduced to insufficient levels in IPF, which in
turn accelerates cellular senescence and provokes pro-
fibrotic myofibroblast differentiation [28, 29]. As these
effects appear to be mediated through TGFβ signaling,
upregulation of TGFBR2 in IPF-ECs may indicate IPF-
specific perturbation in the autophagy cascade.
Our study is based on fresh, native samples from a
rare patient cohort and hence provides a valuable re-
source for IPF research. It is important, however, to
mention also the limitations of our study: First, our
study is based on a limited number of cases, which pre-
cludes that robust, general conclusions can be drawn.
Second, the reference cohort was based on patients with
various kinds of non-IPF lung diseases, rather than
healthy individuals. Third, our study is descriptive,
meaning that causal links or rational therapeutic targets
cannot be established. Fourth, our study is ultimately
based on a single technological platform, i.e., RNA-
sequencing, and does not report protein-level data.
Conclusion
Taken altogether, we here provide a comprehensive, mo-
lecular characterization of IPF-ECs generated ex vivo
from IPF patients. Our results suggest that the transcrip-
tome of IPF-ECs is clearly distinct from non-IPF-ECs
and dominated by signatures whose underlying bio-
logical processes are plausibly involved in IPF pathogen-
esis, such as hypoxia, bacteria, metabolism and
development. Further research is warranted to decipher
the suitability of ECs as a cell-based medicinal product
for anti-fibrotic, epithelium-regenerating treatment of
IPF.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12931-020-01414-z.
Additional file 1: Supplementary Table 1. List of Differentially
Expressed Genes. A total of 199 genes were differentially expressed in
MSC-like cell-derived ECs from IPF versus non-IPF patients, with 80 genes
upregulated and 119 genes downregulated in IPF-ECs. Abbreviations used:
CPM, counts per million (reads mapped); EC, epithelial cell; FC, fold
change; FDR, false discovery rate; IPF, idiopathic pulmonary fibrosis; MSC,
mesenchymal stem cell.
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Additional file 2: Supplementary Table 2. Patient Characteristics of
qPCR Validation Cohort (n = 16). Abbreviations used: IPF, idiopathic
pulmonary fibrosis; ILD, interstitial lung disease.
Additional file 3: Supplementary Figure 1. qPCR Validation of RNA-
Sequencing Results and Comparison to a Published Dataset. (A) TaqMan-
based qPCR analysis of 5 key genes in independent cohorts of IPF (n = 9)
and non-IPF patients (n = 7; one patient overlapping with the RNA-
sequencing analysis). (B) Expression levels of the 5 key genes in IPF and
non-IPF patients from the GSE134692 dataset and two-tiered comparison
to our data (same direction of regulation – yes/no). Abbreviations used:
CPM, counts per million (reads mapped); IPF, idiopathic pulmonary
fibrosis.
Abbreviations
EC: Epithelial cell; FDR: False discovery rate; GO: Gene ontology;
ILD: Interstitial lung disease; IPF: Idiopathic pulmonary fibrosis; KEGG: Kyoto
encyclopedia of genes and genomes; MSC: Mesenchymal stem cell;
PCA: Principal component analysis
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